This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Hematology/ Hematologic Malignancies  • Anemias  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study of long-term mortality associated with aprotinin by Dr Mangano and colleagues¹ did not enroll all patients with coronary artery bypass graft (CABG) surgery in the 69 designated medical centers. There is a potential for site-level bias related to unequal enrollment between European and North American centers, corresponding differences in medication use, and possible associated variations in the quality of care. Based on information from the Web site of the Ischemia Research and Education Foundation describing 70 sites,² 40 were located in North America, 24 in Europe, and 6 elsewhere. Combining this information with the data given in Table 1,¹ it appears that each North American site enrolled a mean of 45 patients during the study period, whereas each European site contributed a mean of 87 patients. Each institution would have been expected to contribute a total of about 180 patients during the study period of . . . [Full Text of this Article]

Elke Scharnetzky, MD, PhD
scharnet@bips.uni-bremen.de

Walter Schill, PhD; Edeltraut Garbe, MD, PhD
Bremen Institute for Prevention Research and Social Medicine (BIPS)
Bremen University
Bremen, Germany

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Steven G. Coca and Chirag R. Parikh
JAMA. 2007;297(22):2475-2476.
EXTRACT | FULL TEXT  

Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Jeffrey Shuhaiber
JAMA. 2007;297(22):2476.
EXTRACT | FULL TEXT  

Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Robert H. Habib, Anoar Zacharias, and Thomas A. Schwann
JAMA. 2007;297(22):2476-2477.
EXTRACT | FULL TEXT  

Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery—Reply
Dennis T. Mangano
JAMA. 2007;297(22):2477.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery
Dennis T. Mangano, Yinghui Miao, Alain Vuylsteke, Iulia C. Tudor, Rajiv Juneja, Daniela Filipescu, Andreas Hoeft, Manuel L. Fontes, Zak Hillel, Elisabeth Ott, Tatiana Titov, Cynthia Dietzel, Jack Levin, and for the Investigators of The Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation
JAMA. 2007;297(5):471-479.
ABSTRACT | FULL TEXT